Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Weis, Sebastian ^a,b   Franke, Annegret ^a   Berg, Thomas ^c   Mössner, Joachim ^a   Fleig, Wolfgang E ^a   Schoppmeyer, Konrad ^d  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Institute of Gastroenterology and Rheumatology   (Germany)

^d Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALCOHOL; ANTINEOPLASTIC AGENT;

ABLATION THERAPY; ACUTE KIDNEY FAILURE; CANCER THERAPY; CHEMOEMBOLIZATION; EARLY CANCER; EFFICACY PARAMETERS; FEVER; HOSPITALIZATION; HUMAN; HYPOTENSION; LIVER CELL CARCINOMA; META ANALYSIS; METHODOLOGY; OVERALL SURVIVAL; PAIN; PERCUTANEOUS ACETIC ACID INJECTION; PERCUTANEOUS ALCOHOL INJECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; RISK REDUCTION; SAFETY PROCEDURE; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UREMIA; ADULT; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CUTANEOUS DRUG ADMINISTRATION; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR VOLUME;

ACETIC ACID; ADMINISTRATION, CUTANEOUS; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; ETHANOL; HUMANS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR BURDEN;

EID: 85016446409     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006745.pub3     Document Type: Review

References (88)

1. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Annals of Surgery 2005;242(1):36-42.
2. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54(8):1151-6.
3. Ohnishi K. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepato-Gastroenterology 1998;45:1254-8.
4. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27(1):67-72.
5. Bottelli R, Iamoni G, Gelosa F, Caspani B, Cecconi P, Zavaglia C, et al. Interstitial laser photocoagulation (ILP) vs percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma (HCC): preliminary results of a randomized pilot study [EASL abstract]. Journal of Hepatology 1997;26:S141.
6. Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27(6):1578-83.
7. Danila M, Sporea I, Sirli R, Popescu A. Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma - results obtained from a series of 88 cases. Journal of Gastrointestinal and Liver Diseases 2009;18(3):317-22.
8. Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World Journal of Gastroenterology 2006;12(23):3707-15.
9. Huo TL, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scandinavian Journal of Gastroenterology 2002;37(3):350-5.
10. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scandinavian Journal of Gastroenterology 2003;38(7):770-8.
11. Huo T, Huang YH, Wu JC, Chiang JH, Lee PC, Chang FY, et al. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Alimentary Pharmacology and Therapeutics 2004;19(12):1301-8.
12. Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatology Research 2009;39(6):553-62.
13. Lencioni R, Crocetti L, Cioni D, Della Pina C, Oliveri F, De Simone P, et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. Journal of Vascular and Interventional Radiology 2010;21(10):1533-8.
14. Orlando A, Cottone M, Virdone R, Parisi P, Sciarrino E, Maringhini A, et al. Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection: a trial with a comparison group. Scandinavian Journal of Gastroenterology 1997;32(6):598-603.
15. Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. European Journal of Surgical Oncology 2010;36(3):257-63.
16. Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, et al. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World Journal of Gastroenterology 2011;17(26):3126-32.
17. Sarin SK, Sreenivas DV, Saraya A, Mehta S, Lahoti D, Malhotra V. Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 1994;6(11):999-1004.
18. Tsai WL, Cheng JS, Lai KH, Lin CP, Lo GH, Hsu PI, et al. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study. Alimentary Pharmacology and Therapeutics 2008;28(3):304-11.
19. NCT00357422. Prospective randomized trial of the effective therapy for small, solitary HCC comparing operation and percutaneous ethanol injection therapy. clinicaltrials.gov/ct2/show/NCT00357422 (accessed 7 August 2014).
20. NCT00357474. A multicenter, randomized, controlled trial of the effective therapy for multiple, small hepatocellular carcinomas: comparing transarterial chemoembolization with percutaneous ethanol injection therapy. clinicaltrials.gov/ct2/show/NCT00357474 (accessed 7 August 2014).
21. Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006935]
22. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000;32:1224-9.
23. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007611.pub2]
24. Begg CB, Mazumar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101.
25. Bismuth H, Majno PE. Hepatobiliary surgery. Journal of Hepatology 2000;32:208-24.
26. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
27. Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterology 2009;11(9):31.
28. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
29. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
30. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology 2001;35:421-30.
31. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology 2008;43(6):717-35.
32. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality of cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 2003;348:1625-38.
33. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49(2):453-9.
34. Coleman MP, Gatta G, Verdeccia A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology 2003;14(Suppl 5):V128-49.
35. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 27 November 2014).
36. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56(4):908-43.
37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analyses detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
38. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine 1999;340:745-50.
39. El-Serag H. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-34.
40. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
41. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003046.pub2]
42. Gluud LL. Bias in Clinical Intervention Research [doctoral dissertation]. Copenhagen: Eget forlag, 2005.
43. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 6. Art. No.: LIVER.
44. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336:924-6.
45. Heffernan N, Webster K, Odom L, Martone M, Passik S, Bookbinder M, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy - hepatobiliary questionnaire. Journal of Clinical Oncology 2002;20(9):2229-39.
46. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
47. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
49. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
50. Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. International Journal of Epidemiology 2009;38:1497-511.
51. Lencioni R, Pinto F, Bassi AM, Moretti M, Di Giulio M, Marchi S, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: an European experience. European Radiology 1997;7:514-9.
52. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228(1):235-40.
53. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127(6):1714-23.
54. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolodi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197(1):101-8.
55. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8.
56. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
57. Macaskill P, Walter SD, Irwing L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20:641-54.
58. Machin D, Stenning SP, Parmar MK, Fayers PM, Girling DJ, Stephens RJ, et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clinical Oncology 1997;9:100-14.
59. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996;334:693-9.
60. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
61. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection. Hepatology 1996;24:1379-85.
62. Ohnishi K, Nomura F, Ito S, Fujiwara K. Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996;23:994-1002.
63. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27(1):67-72.
64. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]
65. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. International Journal of Cancer 2001;94:153-6.
66. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74-108.
67. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
68. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
69. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics, 2007. seer.cancer.gov/csr/1975_2001/ (accessed 14 July 2014).
70. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
71. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
72. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
73. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
74. Sersté T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, Farges O, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology 2012;55:800-6.
75. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129(1):122-30.
76. Sørensen HT, Mellemkjær L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. Journal of Clinical Gastroenterology 2003;36:356-9.
77. Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transplantation 2000;6:67-72.
78. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
79. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
80. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 14 July 2014).
81. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Annals of Surgery 2013;257:929-37.
82. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD003046.pub3]
83. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
84. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology 2009;9:86.
85. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
86. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-13.
87. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transplantation 2002;8(9):765-74.
88. Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006745.pub2]